A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC

This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour. Investigators hypothesize SABR will result in higher rates of freedom from local progression (FFLP) at 2 years compared to percutaneous thermal ablation ± TACE or transarterial therapies (TACE/TARE).The study will also look at other impor

Trial Details

NCT ID
NCT07628751
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Stereotactic Ablative Body Radiotherapy (SABR)
  • Therapies
Locations (sample)
  • Waratah, Australia|-32.90667,151.72647
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • 1\) Histological or radiological diagnosis of single, new HCC with largest diameter =8 cm (BCLC stage 0 or A).
  • a) If prior history of HCC, the prior HCC must have been:
  • Early stage, solitary HCC, =5 cm in size and,
  • Have arisen within a different liver segment to the current HCC and,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →